11:26 AM EST, 01/14/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.

Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.

Separately, Acadia Pharmaceuticals ( ACAD ) said it expects full-year 2025 net sales to top $1 billion for the first time in company history.

The company's shares were down 4.9% in recent trading.

Price: 17.03, Change: -0.87, Percent Change: -4.86